Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Codexis (CDXS – Research Report), Salesforce (CRM – Research Report) and SEMrush Holdings (SEMR – Research Report).
Codexis (CDXS)
In a report released today, Allison Bratzel from Piper Sandler reiterated a Buy rating on Codexis, with a price target of $14.00. The company’s shares closed last Friday at $2.89, close to its 52-week low of $2.19.
According to TipRanks.com, Bratzel is ranked #2688 out of 8551 analysts.
Codexis has an analyst consensus of Moderate Buy, with a price target consensus of $8.90, representing a 151.4% upside. In a report issued on August 4, Craig-Hallum also maintained a Buy rating on the stock with a $11.00 price target.
See the top stocks recommended by analysts >>
Salesforce (CRM)
Bernstein analyst Mark Moerdler maintained a Sell rating on Salesforce today and set a price target of $153.00. The company’s shares closed last Friday at $214.59.
According to TipRanks.com, Moerdler is a 5-star analyst with an average return of
Currently, the analyst consensus on Salesforce is a Moderate Buy with an average price target of $238.04.
SEMrush Holdings (SEMR)
Piper Sandler analyst Clarke Jeffries maintained a Buy rating on SEMrush Holdings today and set a price target of $12.00. The company’s shares closed last Friday at $10.47.
According to TipRanks.com, Jeffries is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
SEMrush Holdings has an analyst consensus of Strong Buy, with a price target consensus of $11.83, representing a 19.7% upside. In a report issued on August 4, J.P. Morgan also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CDXS:
- CDXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
- Codexis sees FY23 product revenue $30M-$35M
- Codexis sees Q2 revenue $21M-$22M, consensus $18.09M
- Codexis to discontinue developments in Biotherapeutics, reduce headcount by 25%
